Researcher discovers antibiotic useful for localized treatment of bone wear

Total joint replacement surgeries can help relieve joint pain common in people with conditions like osteoarthritis. But sometimes, the debris from prosthetic joints leads to aseptic loosening, or disintegration of surrounding bones. In 2009, a Wayne State University researcher determined that the anti-inflammatory antibiotic erythromycin can prevent and treat such disintegration. There was one caveat, however: there are side effects associated with long-term usage of erythromycin.

But Weiping Ren, M.D., Ph.D., associate professor of biomedical engineering in WSU's College of Engineering, has found a solution. Erythromycin can be administered directly at the site of , rather than orally, so the whole body is not affected. The details of Ren's study are published in the August 2011 issue of Clinical Orthopaedics and Related Research.

"Although oral erythromycin reportedly inhibits inflammation in patients with aseptic loosening, long-term systematic (oral) erythromycin treatment is not recommended," said Ren.

Used primarily for its antimicrobial properties, erythromycin is used to treat conditions like and , both caused by . In addition to fighting bacteria, erythromycin reduces inflammation, making it a successful treatment for aseptic loosening.

"But long-term systemic use of erythromycin raises concerns about various side effects, including , and gastrointestinal discomfort," said Ren. "We hypothesized that it may be advantageous to restrict erythromycin delivery to the inflammatory tissue around the implant to avoid these side effects."

To test his idea, Ren implanted metal pins coated with erythromycin in the inflamed tissue surrounding the prosthetic joint. He measured bone growth and implant stability, both indicators of how well the prosthesis integrates with the bone, and analyzed microscopic images of the periprosthetic tissue — the affected tissue surrounding the prosthesis.

Ren found that at very low doses – about a quarter of the dose used for killing bacteria – erythromycin effectively reduces aseptic loosening inflammation. "At the same time, we confirmed that oral erythromycin can be effectively delivered into the periprosthetic tissues, supporting our hypothesis that oral erythromycin can be used as one of the nonsurgical treatment methods to extend implant longevity," said Ren.

By extending implant longevity, localized erythromycin will safely treat aseptic loosening and reduce the likelihood that patients with the condition will need revision surgery. "Medical insurance costs will be greatly reduced, because revision surgery is much more expensive than primary surgery," said Ren.

Provided by Wayne State University - Office of the Vice President for Research

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Erythromycin A produced in E. coli for first time

Nov 24, 2010

(PhysOrg.com) -- Researchers at Tufts University School of Engineering have reported the first successful production of the antibiotic erythromycin A, and two variations, using E. coli as the production host. ...

Scientists discover how some bacteria survive antibiotics

Apr 30, 2008

Researchers at the University of Illinois at Chicago have discovered how some bacteria can survive antibiotic treatment by turning on resistance mechanisms when exposed to the drugs. The findings, published in the April 24 ...

Recommended for you

Team finds key signaling pathway in cause of preeclampsia

15 hours ago

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause ...

Rapid test to diagnose severe sepsis

19 hours ago

A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

User comments